A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid.

Trial Profile

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2010

At a glance

  • Drugs ABT 384 (Primary)
  • Indications Alzheimer's disease; Neurological disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 13 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov
    • 01 Jul 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top